Gene analysis may unlock secrets of bone marrow transplant complication

NCT ID NCT03136757

Terminated Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines tissue samples from patients who developed graft-versus-host disease (GVHD) after a stem cell transplant. Researchers use a technology called nCounter to measure the activity of 800 immune-related genes in these samples. The goal is to identify a unique molecular pattern that could make GVHD diagnosis easier and reveal new pathways for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If a unique molecular signature is found, it could make GVHD diagnosis faster and more accurate, and point toward new treatments.
What could go wrong: This is an observational analysis of stored samples, not a treatment trial. It may not find a clear signature, and any potential therapies would require many more years of research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE HEMATOPOIETIC STEM CELLS

Contacts and locations

Locations

CHU Amiens Picardie

Amiens, Picardie, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.